Event-Driven Stocks

Vitro Biopharma, Inc.

Healthcare · Biological Products, (No Diagnostic Substances) · NV · SEC filings ↗ · Compare ⊕

Signs● 3 good● 4 warning● 3 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY15FY14
Revenue$2.1M$1.9M$1.8M$3.3M$77,801$119,718
Operating income−$5.0M−$9.2M−$5.4M−$6.0M−$158,133−$171,041
Net income−$10.9M−$9.9M−$5.4M−$6.9M−$245,865−$246,527
Total assets$4.9M$5.2M$8.3M$8.6M$116,099$105,582
Total liabilities$21.3M$14.2M$9.4M$5.7M$2.5M$2.3M
Equity−$16.3M−$9.0M−$1.1M$2.8M−$2.4M−$2.2M
EPS (diluted)$-2.44$-2.21$-1.21$-1.87—$-0.01
Shares out.4.5M4.4M4.4M4.4M20.0M19.8M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−244.2%
Net margin
−527.6%
Return on equity
66.4%
Return on assets
−220.2%
Return on capital (ROCE)
—
Liabilities / assets
431.4%
Debt / equity
—
Book value / share
$-3.66
Revenue growth (YoY)
10.8%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-46.34distress
Accruals / assets
−168.7%clean
Piotroski F-Score
4/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
45
/ 100
Profitability 25Growth 100Catalyst 33Earnings quality 67Financial strength 0

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 3 severe● 4 warning● 3 good
  • Negative shareholder equity
  • Altman Z″ in the distress zone
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • Operating losses (negative operating margin)
  • Reported a net loss
  • High leverage (liabilities > 70% of assets)
  • Negative operating cash flow
  • Strong return on equity (>15%)
  • Revenue is growing year-over-year
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.